New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
08:46 EDTEWEdwards Lifesciences a takeover candidate, says Canaccord
Canaccord believes the unexpected simultaneous approval of Edwards Lifesciences' SAPIEN XT heart valve and its green light for XT to treat high risk patients with severe aortic stenosis will cause Street estimates to increase. The firm views Edwards as an attractive acquisition candidate, citing its focus on a large and growing market and its high operating margins, and has a Buy rating with a $96 price target on the stock.
News For EW From The Last 14 Days
Check below for free stories on EW the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 24, 2014
21:54 EDTEWPiper Jaffray to hold a bus tour
Subscribe for More Information
August 21, 2014
08:29 EDTEWEdwards Lifesciences price target raised to $120 from $97 at JMP Securities
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use